Alumis reports LUMUS topline, misses overall endpoints
Alumis said LUMUS Phase 2b topline results missed primary and secondary endpoints overall, but showed robust responses in IFNGS-high patients.
Alumis announced LUMUS Phase 2b topline results: the trial missed primary and secondary endpoints overall but showed robust responses in IFNGS—high patients.Key Highlights:Original SEC Filing: ALUMIS INC. [ ALMS ] - 8-K - Sep.
01, 2026This is an AI-powered summary.
It may contain inaccuracies.
Cons…